A new partnership between Cochrane’s publishing partner Wiley and the medical AI platform OpenEvidence will see Cochrane evidence helping to inform the platform’s users, including more than 40% of US physicians.
Wiley will license a comprehensive portfolio of scientific and medical content to OpenEvidence, including the Cochrane Database of Systematic Reviews, the home of gold-standard evidence syntheses, widely used to inform clinical guidelines worldwide.
"Cochrane systematic reviews are relied upon by evidence users worldwide, from patients and healthcare professionals to guideline-setters and policymakers," said Karla Soares-Weiser, CEO of Cochrane. "AI is rapidly changing the ways that people use and access evidence, and we hope that this partnership helps to ensure that outputs from AI-powered tools are based on the best possible evidence."
The partnership includes Cochrane Clinical Answers, a curated collection of actionable clinical insights drawn from Cochrane reviews. Developed by experts and grounded in Cochrane’s world‑leading methodological standards, Cochrane Clinical Answers translate complex research into practical insights. Each answer distils high‑quality evidence into an accessible format that supports rapid clinical decision‑making at the point of care, and will now help to inform OpenEvidence users.
“The gap between published research and clinical practice has persisted for decades,” said Daniel Nadler, founder of OpenEvidence. “Every content partnership that puts peer-reviewed evidence directly into the physician’s workflow makes that gap narrower. This one makes it meaningfully so.”
The partnership also includes Wiley’s portfolio of over 400 medical journals and books, including authoritative medical references such as Holland-Frei Cancer Medicine, Rook's Dermatology Handbook, and Yamada's Textbook of Gastroenterology.
"At the end of the day, we believe doctors will be able to make better decisions because we’re bringing Wiley’s vast portfolio of peer-reviewed scientific and medical content into OpenEvidence, where those decisions are getting made," said Matt Kissner, president and CEO of Wiley. "We’re excited about this partnership, which reflects our broader commitment to integrating trusted scientific knowledge into the technologies driving innovation across healthcare and life sciences."
